<DOC>
	<DOC>NCT01579487</DOC>
	<brief_summary>This study is being performed to follow up on subjects who participated in the initial study (ZA10-001) in 2010.</brief_summary>
	<brief_title>Extended Follow-Up Study for Subjects Who Participated in 2010 Study</brief_title>
	<detailed_description>The primary objective of this investigation is to assess the durability of treatment outcomes with the ZELTIQ System.</detailed_description>
	<mesh_term>Lipid Metabolism Disorders</mesh_term>
	<criteria>1. Subject participated in the ZA10001 study, and received all study treatments. 2. Subject has read and signed a written informed consent form. 1. Subject has had any surgical or aesthetic procedure(s) in or around the abdomen since the completion of the ZA10001 study treatments. 2. Subject is pregnant. 3. Subject is unable or unwilling to comply with the study requirements. 4. Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device. 5. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the integrity of the data.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Lipolysis</keyword>
	<keyword>Cryolipolysis</keyword>
	<keyword>Fat Reduction</keyword>
</DOC>